CUSIP: 75915K200
Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
9,062,294
-
Share change
-
+6,408,887
-
Total reported value
-
$11,330,208
-
Price per share
-
$1.25
-
Number of holders
-
21
-
Value change
-
+$8,032,017
-
Number of buys
-
11
-
Number of sells
-
12
Quarterly Holders Quick Answers
What is CUSIP 75915K200?
CUSIP 75915K200 identifies RGLS - REGULUS THERAPEUTICS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2019
-
Previous quarter:
Q1 2019
Recent filing periods for CUSIP 75915K200:
Institutional Holders of REGULUS THERAPEUTICS INC - COM NEW (RGLS) as of Q2 2019
As of 30 Jun 2019,
REGULUS THERAPEUTICS INC - COM NEW (RGLS) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,062,294 shares.
The largest 10 holders included
NEA Management Company, LLC, BVF INC/IL, Sarissa Capital Management LP, EcoR1 Capital, LLC, Samsara BioCapital, LLC, CVI Holdings, LLC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., and WEDBUSH SECURITIES INC.
This page lists
21
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.